Harpeth Capital Serves as Financial Advisor to IncellDx, Inc.
Harpeth Capital is pleased to announce that it served as financial advisor to IncellDx, Inc., a privately-held molecular diagnostics startup company dedicated to the detection of life threatening viral diseases, in connection with an investment in the Company by Bio-Reference Laboratories, Inc. (NASD:BRLI).
Founded in 2009 and based in Menlo Park, California, the Company’s innovative technology currently targets the risk of developing cervical cancer, which is applicable to the large cervical cancer screening market. Cervical cancer is a leading cause of female mortality from cancer worldwide. IncellDx’s reagents are being used today by a number of reference laboratories.
About IncellDx, Inc.
IncellDx is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDS, hepatitis and organ transplant rejection.
About Bio-Reference Laboratories, Inc.
Publicly-traded BRLI is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. BRLI offers a comprehensive list of laboratory testing services utlized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. BRLI primarily focuses on esoteric testing, molecular diagnostics, anatomical pathology, women’s health and correctional health care.